UB becomes a shareholder of Reveal Genomics, a spin-off born to develop innovative diagnostic tests in oncology


Aleix Prat (Hospital Clínic-UB) and Patricia Villagrasa-González (Reveal Genomics).

Aleix Prat (Hospital Clínic-UB) and Patricia Villagrasa-González (Reveal Genomics).

The University of Barcelona has become a shareholder of Reveal Genomics, a spin-off of Hospital Clínic and Vall d’Hebron Institute of Oncology (VHIO), which plans to develop and market precision diagnostic tools in oncology based on he combination of different genomic data. First, the spin-off will focus on the improvement of breast cancer diagnosis with tools that enable them to personalize the treatment of the disease.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.